Drug Profile
S 309721
Alternative Names: S 30972-1Latest Information Update: 18 Apr 2002
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Class Antineoplastics
- Mechanism of Action DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 18 Apr 2002 No development reported - Preclinical for Cancer in Belgium (unspecified route)
- 18 Apr 2002 No development reported - Preclinical for Cancer in France (unspecified route)
- 10 Oct 2000 New profile